|View printer-friendly version|
Spring Bank Announces Inarigivir Data Presentations at AASLD Conference
The poster presentation, entitled Inarigivir is a Novel Selective Inhibitor of the HBV Replicase Complex In Vitro, has been selected by AASLD’s Scientific Program Committee as a Poster of Distinction and will highlight the novel direct-acting anti-viral mechanism of action of inarigivir, an orally administered RIG-I agonist. Posters of Distinction are classified as being in the top 10% of scored poster abstracts and will receive special recognition at AASLD’s poster hall.
The oral presentation, entitled Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response, will review the full results from the first three cohorts of Spring Bank’s Phase 2 ACHIEVE trial in patients with chronic hepatitis B (HBV) infection. Twelve-week inarigivir monotherapy demonstrated a favorable safety profile with significant antiviral activity on all viral parameters, including HBV DNA, HBV RNA, and HBsAg, with an enhanced response in HBeAg-negative patients.
“We are honored to have been selected as a Poster of Distinction by the Scientific Program Committee and pleased to see the team’s hard work recognized by this distinguished group,” said Dr.
For investor and media inquires:
Source: Spring Bank Pharmaceuticals
Source: Spring Bank Pharmaceuticals, Inc.